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Abstract 
 
 Spinal cord injury (SCI) results in varying degrees of paralysis, loss of normal sensory 
function and, oftentimes, chronic pain originating below the level of injury.  Post-SCI pain tends 
to be resistant to traditional analgesic therapies and has been shown to impair recovery of 
function, making it a significant healthcare concern.  Approximately one third of SCI patients 
report abdominal pain as a primary and severe symptom with marked similarity to other 
functional gastrointestinal pain disorders (e.g. irritable bowel). The etiology of this intense pain 
phenotype is unclear given that visceral organs are left uninjured in SCI. Here we examine 
changes in expression of pain-relevant genes in the colon following SCI both over time and 
between two different specific injury parameters. Mice underwent spinal contusion injury 
resulting in complete paralysis below the level of the forelimbs (two injury severity conditions), 
were then sacrificed 1 or 7 days following SCI, and alterations in pain-relevant gene expression 
were determined using quantitative RT-PCR. Additionally, the presence of inflammation at 1 day 
post-SCI was performed using hematoxylin and eosin staining. The data indicate a pattern of 
both time- and injury-dependent differential gene expression within the colon following SCI 
including Gfrα1-3, Trkb, Trkc, Asic1, Asic2, and Calcα. Further, pilot hematoxylin and eosin 
studies suggest that differences in expression in the first 24 hours post-injury may be 
inflammation independent. Differentially expressed genes in the periphery may offer insight into 
novel therapeutic targets for prevention and treatment of abdominal pain following SCI. 
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Introduction 
Background 
Spinal cord injury (SCI), a debilitating and life-altering injury, affects as many as 195 per 
million people worldwide, with the United States among one of the top affected developed 
countries at ~40 cases per million people (Massetti & Stein, 2017). SCI is more common in men 
with a nearly four-fold increased prevalence between men and women (Massetti & Stein, 2017). 
Additionally, the average age of SCI occurrence is around the age of 40 (Massetti & Stein, 
2017). Although a rare type of injury, SCI has as an unusually high financial burden with the 
annual cost in the United States estimated at ~$9.7 billion per year, therefore demonstrating the 
complex medical needs of this patient population (French et al., 2007; Wyndaele & Wyndaele, 
2006).  
Patients experience varying degrees of paralysis in both voluntary and involuntary 
muscle groups depending on location and severity of injury: tetraplegia or paraplegia (Maynard 
et al., 1997). The most severe paralysis classification is tetraplegia, which is injury to the cervical 
region of the spinal cord with impairment of arms, trunk, legs, and pelvic organs (Maynard et al., 
1997). Paraplegia, on the other hand, refers to injury at any of the other levels of the spinal cord 
(thoracic, lumbar, or sacral) that results in varying degrees of trunk, leg, and pelvic organ 
impairment, depending on the specific level of injury, and no arm impairment (Maynard et al., 
1997). Further, depending on the degree of spinal cord transection, both tetraplegia and 
paraplegia can either be complete or incomplete (Maynard et al., 1997). If sensory or motor 
function is found anywhere below level of injury, including the sacral region, then the injury is 
considered incomplete (Maynard et al., 1997). Complete injuries, as the classification name 
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suggests, result in a complete absence of sensory and motor function below level of injury, 
particularly in the sacral region (Maynard et al., 1997). 
The dual innervation of the somatic nervous system (SNS) and autonomic nervous 
system (ANS) is essential for proper organ function (Alexander et al., 2009). In SCI, these two 
pathways are often disrupted, with increasing severity as the level of injury gets higher, leading 
to many commonly experienced side effects that require close medical monitoring (Alexander et 
al., 2009). For example, in the cardiovascular and respiratory systems, SCI patients can have 
difficulty controlling blood pressure and heart rate, and develop shortness of breath, an inability 
to clear their airways by coughing, and/or heightened bronchial responses (Alexander et al., 
2009). Patients also may experience problems with temperature regulation as the innervation of 
their sweat glands can be affected by SCI too (Alexander et al., 2009). Lastly, patients often lose 
control of their visceral organs including the bladder, bowel, and sexual organs (Alexander et al., 
2009). While the aforementioned SCI related side effects are thought of as loss-of-function, one 
major symptom exists that would be considered gain-of-function: pain.  
 Pain, defined as “the unpleasant sensory and emotional experience associated with actual 
or potential tissue damage” (International Association for the Study of Pain) can be one of the 
most troublesome symptoms to treat in this patient population. Although SCI patients cannot feel 
their lower extremities, they experience pain that can severely decrease quality of life as well as 
deter recovery of function (Siddall et al., 2003). Additionally, once pain transitions from an acute 
to a chronic condition, it becomes very difficult to treat with traditional analgesics (Siddall et al., 
2003).  
Not all pain experienced by SCI patients is the same. Researchers have divided SCI-
induced pain into two main categories: nociceptive pain and neuropathic pain (Finnerup & 
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Baastrup, 2012). Neuropathic pain is defined as “pain caused by lesion or disease of the 
somatosensory nervous system” (Finnerup & Baastrup, 2012; Jensen at al., 2011). This type of 
pain has been further classified into at-level and below-level pain and is characterized by both 
spontaneous and stimulus-evoked pain. Patients with neuropathic pain typically describe it as 
“burning,” “tingling,” “pins and needles,” and “shooting” (Finnerup & Baastrup, 2012). 
Alternately, nociceptive pain originates specifically from alterations to the activity of primary 
afferent neurons (International Association for the Study of Pain). Two of the main types of 
nociceptive pain seen in SCI patients are musculoskeletal pain and visceral pain (Finnerup & 
Baastrup, 2012). Much of what we know about post-SCI pain comes from studies on 
musculoskeletal pain. This type of “achy” pain can be caused by overuse of muscles like the 
upper body to compensate for a lack of mobility in lower extremities, poor posture, and muscle 
spasms (Finnerup & Baastrup, 2012).  
Researchers theorize that both peripheral and central sensitization occur following injury, 
which causes the transition from localized acute pain, to chronic widespread pain (Graven-
Nielsen & Arendt-Nielsen, 2010). The International Association for the Study of Pain (IASP) 
defines peripheral sensitization as “increased responsiveness and reduced threshold of 
nociceptive neurons in the periphery to the stimulation of their receptive fields.” This type of 
sensitization is due to inflammatory mediators and neurotrophic factors during injury or 
inflammation that in turn activate G-coupled receptors and tyrosine kinase receptors (Woolf & 
Salter, 2000). When these receptors are activated, tyrosine kinases in the cell can phosphorylate 
sodium channels in the neuron therefore affecting the behavior of the channel by making it easier 
for the channel to be activated and propagate action potentials (Woolf & Salter, 2000). The 
definition of central sensitization is “increased responsiveness of nociceptive neurons in the 
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central nervous system to their normal or subthreshold afferent input” (IASP). In a non-injured 
setting, nociceptors composed of Aδ and C-fibers have their terminals in peripheral tissues 
(Graven-Nielsen & Arendt-Nielsen, 2002). These terminals can be activated by ligands for any 
of the sensory-related receptors found on them (Woolf & Salter, 2000). When sufficiently 
activated, the nociceptors transduce sensory information into action potentials that travel to the 
central terminals in the spinal cord on the dorsal horn (Woolf & Salter, 2000). Once there, 
excitatory glutamate is released and binds to AMPA and kainate ligand-gated ion channels and 
their signals get modulated by spinal cord inhibitory neurons (Woolf & Salter, 2000). In 
pathological injury or inflammatory states, there is an increase of nociceptor signal frequency 
that causes temporal summation and depolarization of additional NMDA receptors and voltage-
gated calcium channels, resulting in action potential discharge windup (Woolf & Salter, 2000). 
These increases in nociceptor discharge frequency or intensity lead to sensations of pain 
experienced by patients (Koltzenburg, 2000). The mechanisms researched for musculoskeletal 
pain can apply to other types of pain, as well. 
Visceral pain refers to pain originating in the abdominal organs and approximately 14-
38% of all SCI patients report abdominal pain as a primary and severe symptom (Ebert, 2012; 
Finnerup et al., 2008). Described by patients as “cramping and tightening,” “tender,” and 
“shooting,” this specific type of pain begins at later time points following the initial injury and is 
accompanied by a host of symptoms similar to those of functional gastrointestinal disorders like 
Irritable Bowel Syndrome (IBS) (Finnerup & Baastrup, 2012). For example, patients report 
constipation, abdominal distension, incontinence, diarrhea, pain worse after eating, and pain 
relieved by bowel movements (Ebert, 2012). The etiology of this intense pain phenotype is 
unknown considering that visceral organs are left without damage following SCI (Finnerup & 
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Baastrup, 2012). Most of the research on post-SCI visceral pain have been clinical studies 
focusing on symptomology. Additionally, literature using animal models of SCI tend to explore 
methods for regaining motor function and, in the pain literature specifically, examining 
musculoskeletal pain. Currently, there is a lack of precise, mechanistic studies for understanding 
SCI visceral pain and which genes and proteins may be playing a role in its induction and 
maintenance. What we can take from the other available literature is that molecular changes 
seem to happen immediately following SCI. Therefore, despite visceral pain being a late onset 
symptom, there may be immediately targetable mechanisms that arise during the early phase 
following injury. If we can identify the early gene(s) involved in the eventual development of 
chronic visceral pain, it may be possible to develop novel precision pain treatment strategies to 
prevent the eventual onset of this phenotype. This type of early intervention is more plausible in 
SCI than in other injury types of injuries as patients seek medical attention immediately at the 
time of injury offering a unique window of opportunity to intervene before the phenotype has 
even been established.  
Targets of Interest 
 The targets we chose to examine are all important for sensory processing. Further, they 
have been implicated, more specifically, in peripheral pain processing and are mechanistically 
tied to the development of pathological pain states responsible for hypersensitivity.  
GDNF family receptors.  The GDNF family receptors are well known for their role in 
the development of both central and peripheral neurons (Airaksinen & Saarma, 2002; Baloh et 
al., 2000). After development, the signaling between these receptors and their respective ligands 
(GFRα1-GDNF, GFRα2-Neurturin, GFRα3-Artemin) is still essential as it helps maintain the 
survival of neurons (Airaksinen & Saarma, 2002). In the peripheral nervous system specifically, 
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and why they are of interest to us in the present study, the GDNF family receptors are involved 
in controlling sensory neuron cell body size, the targets the neurons innervate, and pain 
processing (Airaksinen & Saarma, 2002). As a result, they are interesting potential targets for 
treating pain disorders (Airaksinen & Saarma, 2002). 
 Tyrosine receptor kinases.  Similar to the GDNF family receptors, signaling between 
the tyrosine receptor kinase family and their neurotrophic ligands (NGF-TrkA, BDNF-TrkB, 
NT-3-TrkC) is important for neural development, adult sensory neuron survival and 
regeneration, and nociceptor function (Khan & Smith, 2015; Jankowski & Koerber, 2010; Shu et 
al., 1999; Lindsay, 1996). Mutations of TrkA in humans has been linked to the congenital 
insensitivity to pain while manipulations of TrkB and TrkC have both been associated with 
alterations in pain development and persistence (Indo, 2001; Wang et al., 2009; Jankowski & 
Koerber, 2010). 
 Transient receptor potential channels.  Both transient receptor potential vanilloid 1 
(TRPV1) and transient receptor potential ankyrin 1 (TRPA1) have been implicated in pain 
transmission. TRPV1, most well-known for its role as the capsaicin receptor, is highly associated 
with visceral pain pathologies like IBS as increased TRPV1-immunoreactive nerve fibers have 
been found in colon biopsies from IBS patients (Akbar et al., 2008). TRPA1 seems to be more 
important in inflammatory models of pain, such as formalin, as blocking it can attenuate 
inflammation-associated behavioral and physiological activity (McNamara et al., 2007).  
 Acid sensing ion channels.  The acid sensing ion channels (ASICs) are known for their 
sensitivity in detecting pH changes, however they also seem to be important players for the 
transduction of mechanical stimuli in the viscera, as well as both contributing to and modulating 
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pain responsiveness after inflammatory events (Lingueglia, 2007; Staniland & McMahon, 2012; 
Mamet et al., 2002). 
 Purinergic receptors.  The purinergic receptors P2X3 (ATP receptor) and P2Y1 (ADP 
receptor) are also important for peripheral pain processing (Hockley et al., 2016). P2X3 has been 
shown to be a contributor to both chronic inflammatory pain states as well as colon mechanical 
hypersensitivity in IBS (North, 2004; Shinoda et al., 2009). Similarly, P2Y1 activation via ADP 
has been highlighted as a mechanism for human and mouse visceral pain pathologies (Hockley et 
al., 2016). 
 Piezo-type mechanosensitive ion channel component 2.  Piezo2 has emerged as a main 
sensitive mechanical transducer, mostly researched in skin (Yang et al., 2016). When examined 
for a role in visceral mechanotransduction, researchers found that Piezo2 knockdown in the 
dorsal root ganglion (DRG) decreased visceral responses to stimuli, suggesting it could be 
important (Yang et al., 2016). 
 Calcitonin-related polypeptide alpha.  Calca, the gene that encodes calcitonin gene 
related peptide (CGRP), has been associated with migraines and inflammatory pain (Ho et al., 
2010; Hernanz et al., 2003; Donnerer et al., 1992). Further, CGRP is released by peptidergic 
nociceptors in response to noxious heat and inflammatory mediators (Kessler et al., 1999). If 
inflammation is present in the colon following SCI, it is possible CGRP could be involved in 
post-SCI visceral pain. 
Statement of Objective 
Due to the marked similarities between post-SCI visceral pain and gastrointestinal 
disease symptomology, the purpose of this study was to determine potential alterations in colon-
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specific gene expression in the development of colon (i.e. visceral) pain following SCI.  We 
evaluated gene expression changes over the first week following injury and also compared across 
different injuries to examine 1) the dynamic pattern of altered gene expression immediately post-
SCI and 2) whether this pattern differs with injury. Toward this goal we used a mouse model of 
SCI to quantitatively analyze differential gene expression in the colon. We identified time- and 
injury-specific changes in colon-specific gene expression of several targets including Gfrα1-3, 
Trkb, Trkc, Asic1, Asic2, and Calc. This study is a first step in identifying potential therapeutic 
targets to increase the specificity of pain treatment in patients. 
Methods 
Animals 
 34 female C57BL/6 mice were used that were either ordered directly from Jackson 
Laboratories or bred in-house from Jackson Laboratories founder strains. We decided to use 
females because females are more likely to develop pain and they weigh less which makes them 
less likely to develop scoliosis or other postural changes that could affect behavioral outcomes 
(Wiesenfeld-Hallin, 2005). Naïve animals were kept in on-site animal facilities and injured 
animals were moved to an SCI-specific on-site animal room following any surgical procedures. 
All animals were kept on a regular dark/light schedule and given food and water ad libitum. 
Injured animals and shams were given nutrient supplements in addition to regular food and 
water. Injured and sham animals were also given injections of 2cc saline once a day for the first 
four days following surgery (including day of surgery) and their bladders were expressed twice 
daily. All animals maintained proper bowel function. Animal health was closely monitored and, 
although not experienced by any of the animals used for tissue in this study, if any animals were 
to show signs of excess pain/distress or poor overall health (weight loss greater than 15%, 
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ruffling/hunching), they would have been euthanized. All experiments were in conducted in 
accordance with protocols approved by the UCONN Health Institutional Animal Care and Use 
Committee.  All animal facilities at UConn Health are fully accredited by the AAALAC-
international since June 1977. The experimental cohorts of animals used in the study were as 
follows: naïve; 1 day post-SCI sham; 7 days post-SCI sham; 1 day post-SCI of 65kD, 1 second 
dwell time; 7 days post-SCI of 65kD, 1 second dwell time; 1 day post-SCI of 70kD, 10 second 
dwell time; and 7 days post-SCI, 10 second dwell time. 
Spinal Cord Injury Model 
 Mice were initially anesthetized using isoflurane flowed through to a plexiglass 
anesthesia induction chamber via an anesthesia machine set to 2.5% flow rate concentration. 
Once unconscious, mice were secured to an oxygen mask flowing both oxygen and 1.5% flow 
rate concentration of isoflurane for maintenance of anesthetic level during surgery. Each mouse’s 
back fur was then shaved and the skin sterilized using iodine and chlorhexidine. A small portion 
of the spinal cord around T10/T11 was exposed via delamination and cleared of bone debris. The 
mouse was then secured underneath the piston of an Infinite Horizons impactor (Precision 
Systems and Instrumentation; Fairfax Station, VA) and injury parameters were programed to 
deliver a specific severity of contusion injury (either 70kD impact, 10 seconds dwell time OR  
65kD impact, 1 second dwell time). Two injuries were performed see if different injury severities 
may lead to different patterns of expression. The 70kD, 10 second dwell time injury leads to a 
much greater injury, closer to a transection, with little to no recovery of function overtime (i.e. 
bladder and motor) and are more likely to have severe complications earlier following injury 
resulting in death or euthanasia. The 65kD, 1 second dwell time injury is still severe, but is more 
likely to be followed by some recovery of function (at later timepoints than those used in this 
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study) and the mice have better overall health with increased survival rates. After injury 
induction, the incision was sutured and animals received a 5mg/kg injection of gentamicin 
(Henry Schein; Melville, NY) and allowed to come out of anesthesia under close supervision. 
Mice were given gentamicin injections once daily for the following two days after surgery, as 
well. With both impact severities, the injury resulted in complete paralysis below the level of the 
forelimbs. The mice were sacrificed either 1 day or 7 days after SCI. Sham control surgery 
consisted of spinal cord exposure via delamination and tissue collection at 1 day and 7 days post-
surgery. 
RNA Extraction and Complementary DNA Preparation 
 Animals were perfused with cold saline under anesthesia via transcardial perfusion until 
the exudate ran clear from the atrium. The distal ~1.5 cm of colorectum was collected avoiding 
the inclusion of the anus (i.e. somatic tissues).  Samples were put immediately on dry ice and 
then stored at -80°C for processing in batches. The colon was homogenized in 350µL of a 
mixture of Buffer RLT and 10µL/1mL β-mercaptoethanol until no individual tissue pieces were 
visible and the resulting tissue homogenate was used for collection of total ribonucleic acid 
(RNA) (RNeasy MiniKit; Qiagen; Hilden, Germany). Final RNA concentrations and RNA 
quality were determined using a Biospectrometer (Eppendorf; Hamburg, Germany). A 260/280 
value of at least 2.00 was deemed as usable quality of RNA. Total RNA with a starting 
concentration of 500ng per sample was made into complementary deoxyribonucleic acid 
(cDNA) using the iScript cDNA Synthesis Kit according to the manufacturer’s instructions (Bio-
Rad; Hercules, CA). 
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Quantitative RT-PCR 
 Quantitative RT-PCR was performed using SsoAdvanced™ Universal SYBR® Green 
Supermix (Bio-Rad; Hercules, CA) with custom primers for each candidate gene (IDT; 
Coralville, IA). Primers were created for the following targets: GDNF family receptor alpha 1-3 
(Gfrα1, Gfrα2, Gfrα3),  tyrosine receptor kinase a-c (Trka, Trkb, Trkc), transient receptor 
potential vanilloid 1 (Trpv1), transient receptor potential ankyrin 1 (Trpa1), acid sensing ion 
channels 1-3 (Asic1, Asic2, Asic3), purinergic receptor P2y 1 (P2y1), purinergic receptor P2x 3 
(P2x3), piezo-type mechanosensitive ion channel component 2 (Piezo2), calcitonin-related 
polypeptide alpha (Calc-α), and glyceraldehyde 3-phosphate dehydrogenase (Gapdh) (Table 1). 
The primers were all determined to be 100% efficient (defined as 95% or better amplification 
between PCR cycles at specific concentrations of template/sample and primer used) using 
efficiency analysis (Pfaffl, 2001). Melt curve analyses were performed to confirm single product 
amplification, followed by PCR product analysis via gel electrophoresis to confirm that a single 
product was produced. All primers were used at their optimal concentration to maintain 
efficiency consistency between targets. Each sample was run in duplicate using 500ng of cDNA 
per well. The temperature cycle parameters (StepOne Plus Real-Time PCR System; Applied 
Biosystems; Foster City, CA) and were as follows: 30 seconds at 95°C followed by 40 cycles of 
15 seconds at 95°C and then 60 seconds at 60°C. Following completion of the cycles, the PCR 
machine produced cycle threshold values (Ct values) that denote the number of amplification 
cycles needed for the amount of target product to reach a detectable threshold. Therefore, the 
higher the Ct value, the more cycles it took to detect the product, meaning it was lower in 
abundance in the sample. Gapdh was used as a housekeeping gene for every sample and each 
sample’s respective Gapdh average Ct value was subtracted from the average target gene Ct 
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value in order to calculate the Ct. All subjects for all conditions were then normalized to the 
average of the naïve control condition to calculate Ct (CtSubject -CtNaiveMean). Ct values 
were then converted into fold difference in expression using the 2-Ct method to examine the 
target gene expression differences between conditions.  
Hematoxylin and Eosin Staining 
 We used a hematoxylin and eosin staining as a histological assessment to determine 
whether SCI may cause inflammation in the colon that could be related to alterations in gene 
expression early following injury. Hematoxylin and eosin stain is a common method for 
examining colonic inflammation as it can detect the presence of infiltrating immune cells and 
wall thickening (Wirtz et al., 2007). One naïve and one 1 day post-SCI (70kD, 10 second dwell 
time) animals were first fixed using 4% paraformaldehyde, then their colons were dissected and 
post-fixed for 24 hours in 4% paraformaldehyde, 4% sucrose before subsequent embedding in 
OCT. Colons were cross-sectioned at a thickness of 5 micrometers using a cryostat and placed on 
charged microscope slides for hematoxylin and eosin staining (National Diagnostics; Atlanta, 
Georgia). 
Statistical Analysis 
 One-way Analysis of Variance (ANOVA) were used to determine significant differences 
in gene expression between both naïve, 1 day post-SCI, and 7 days post-SCI time points for both 
injury conditions (70kD, 10 second dwell time and 65kD, 1 second dwell time), as well as naïve, 
1 day sham, and 7 day sham. Planned comparison tests were used to determine an effect of injury 
level on gene expression at both 1 day and 7 days post-SCI. A result was considered significant 
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if the p value was less than or equal to 0.05. Post-hoc analysis was conducted on all significant 
ANOVA using Tukey’s honestly significant difference test (HSD). 
Results 
Differential Gene Expression 
Visceral pain induced by SCI is not a symptom reported by patients until later following 
injury. However, we assessed differences in pain-relevant gene expression at two time points 
across the first week post-SCI to evaluate changes early on that may reflect pathological 
processes that could contribute to subsequent visceral pain. If we can identify and target these 
early changing genes, we could prevent chronic visceral pain before it even starts. We also 
examined two different injury levels following SCI in order to determine injury-specific 
alterations in gene expression. We detected both time and SCI condition significant differences 
for multiple targets.  
GDNF family receptors. We examined expression differences in a group of glial-
derived neurotrophic factor family receptors, Gfrα1-3 (Figure 1). For the severe injury condition 
(70kD, 10 second dwell time), we found a significant difference in expression between naïve, 1 
day post-SCI, and 7 days post-SCI for Gfrα2 (F(2,10) = 5.502, p = 0.024), but not Gfrα1 or 
Gfrα3 (F(2,10) = 3.661, p = 0.064; F(2,10) = 4.059, p = 0.051, respectively). Tukey’s HSD post-
hoc analysis demonstrated elevated Gfrα2 expression at 7 days post-SCI compared to 1 day post-
SCI (p = 0.020). For the moderate injury condition (65kD, 1 second dwell time) we found the 
opposite in that both Gfrα1 and Gfrα3 had significant differences in expression (F(2,10) = 6.460, 
p = 0.016; F(2,10) = 6.112, p = 0.018, respectively), but Gfrα2 did not (F(2,10) = 2.050, p = 
0.179). Tukey’s HSD post-hoc analysis determined that compared to naïve mice, both 1 day and 
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7 days post-SCI animals had reduced Gfrα1 expression (p = 0.026; p = 0.019, respectively), but 
only 1 day post-SCI animals showed a decrease in Gfrα3 (p = 0.016). Similarly, sham surgery 
also demonstrated significant differences in both Gfrα1 and Gfrα3 expression (F(2,11) = 11.431, 
p = 0.002; F(2,11) = 11.028, p = 0.002, respectively). According to Tukey’s HSD post-hoc, 1 
day sham and 7 day sham animals both had decreases in Gfrα1 expression (p = 0.003 for both) 
and Gfrα3 expression (p = 0.003; p = 0.005, respectively) compared to naïve. 
When assessing effect of injury condition (70kD, 10 second dwell time vs. 65kD, 1 
second dwell time) on Gfrα1-3 expression at 1 day post-SCI, we found no significant differences 
(F(1,7) = 0.659, p = 0.444; F(1,7) = 2.212, p = 0.181; F(1,7) = 1.476, p = 0.264, respectively) 
(Figure 1). However, there was a significant effect of injury condition on expression of both 
Gfrα1 and Gfrα3 (F(1,9) = 5.546, p = 0.043; F(1,9) = 5.664, p = 0.041, respectively) at 7 days 
post-SCI, but not Gfrα2 (F(1,9) = 2.015, p = 0.189). There was more Gfrα1 and Gfrα3 
expression in the moderate injury condition (M = 0.31, SD = 0.09; M = 0.49, SD = 0.31, 
respectively) than the severe injury condition (M = 0.18, SD = 0.09; M = 0.19, SD = 0.04). 
Tyrosine receptor kinases.  We also examined differential expression within the family 
of tyrosine receptor kinases, Trka-c (Figure 2). There was a significant difference of Trkc 
expression in the severe injury condition (F(2,10) = 11.581, p = 0.002), but not of Trka or Trkb 
(F(2,10) = 0.915, p = 0.432; F(2,10) = 0.297, p = 0.749, respectively). Tukey’s HSD post-hoc 
analysis showed that, compared to naïve, 1 day post-SCI and 7 day post-SCI animals both had 
decreased expression of Trkc (p = 0.005; p = 0.003, respectively). Moderate injury condition did 
not demonstrate any significant differences in expression of Trka, Trkb, or Trkc (F(2,10) = 
1.713, p = 0.229; F(2,10) = 3.870, p = 0.057; F(2,10) = 0.273, p = 0.767, respectively) and 
15 
 
neither did sham (F(2,11) = 0.453, p = 0.647; F(2,11) = 0.627, p = 0.552; F(2,11) = 2.623, p = 
0.117, respectively). 
In the assessment of injury condition, at day 1 post-SCI, there were no significant 
differences in expression of Trka-c (F(1,7) = 0.050, p = 0.830; F(1,7) = 3.260, p = 0.114; F(1,7) 
= 1.868, p = 0.214, respectively) (Figure 2). At 7 days post-SCI, there was no significant effect 
of injury level on Trka or Trkc expression (F(1,9) = 3.626, p = 0.089; F(1,9) = 3.825, p = 0.082, 
respectively), but there was on Trkb expression (F(1,9) = 6.395, p = 0.032). Trkb expression was 
higher in the moderate injury condition (M = 45.46, SD = 40.29) than the severe injury condition 
(M = 3.81, SD = 5.75).  
Transient receptor potential channels. We also included transient receptor potential 
channels, Trpv1 and Trpa1, in our investigative panel (Figure 3). Severe injury condition 
demonstrated no significant changes in expression for either Trpv1 or Trpa1 (F(2,10) = 1.256, p 
= 0.326; F(2,10) = 0.562, p = 0.587, respectively). Moderate injury condition also did not have 
any significant changes in Trpv1 or Trpa1 expression (F(2,10) = 1.633, p = 0.243; F(2,10) = 
1.246, p = 0.329, respectively). Similarly, shams had no significant changes in expression of 
Trpv1 or Trpa1 either (F(2,11) = 0.255, p = 0.780; F(2,11) = 2.761, p = 0.107, respectively). 
There was no effect of injury condition on expression of Trpv1 or Trpa1 at 1 day post-
SCI (F(1,7) = 0.263, p = 0.624; F(1,7) = 0.302, p = 0.600, respectively) or at 7 days post-SCI 
(F(1,9) = 3.255, p = 0.105; F(1,9) = 3.733, p = 0.085, respectively) (Figure 3). 
Acid sensing ion channels.  When examining the acid sensing ion channels, Asic1-3, we 
found no significant changes in expression for the severe injury condition (F(2,10) = 1.233, p = 
0.332; F(2,10) = 0.716, p = 0.512; F(2,9) = 1.089, p = 0.377, respectively) (Figure 4). Moderate 
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injury condition did not have any significant changes in expression of Asic1-3 either (F(2,10) = 
3.140, p = 0.087; F(2,10) = 1.125, p = 0.363; F(2,9) = 1.152, p = 0.359, respectively). For sham 
treatment, Asic1 and Asic3 had no significant changes in expression (F(2,11) = 0.135, p = 0.875; 
F(2,10) = 0.452, p = 0.649, respectively), however, Asic2 expression was significantly altered 
(F(2,11) = 12.241, p = 0.002). Tukey’s HSD post-hoc analysis determined that, compared to 
naïve, 1 day sham and 7 day sham both had decreased levels of Asic2 (p = 0.001; p = 0.016, 
respectively). 
There was no effect of injury condition on expression of Asic1-3 at 1 day post SCI 
(F(1,7) = 1.106, p = 0.328; F(1,7) = 0.790, p = 0.404; F(1,7) = 0.644, p = 0.449, respectively) 
(Figure 4). However, it did significantly affect expression of Asic1 at 7 days post-SCI (F(1,9) = 
14.186, p = 0.004), but not Asic2 or Asic3 (F(1,9) = 0.743, p = 0.411; F(1,9) = 1.896, p = 0.202). 
Asic1 expression was greater at the moderate injury level (M = 2.47, SD = 1.16) than the severe 
injury level (M = 0.65, SD = 0.28).  
Purinergic receptors. The purinergic receptors P2y1 and P2x3 demonstrated no 
significant changes with severe injury condition (F(2,10) = 0.880, p = 0.445; F(2,10) = 1.179, p 
= 0.347, respectively) (Figure 5). Similarly, moderate injury condition did not display any 
significant changes in P2y1 or P2x3 expression (F(2,10) = 0.638, p = 0.548, F(2,10) = 0.854, p = 
0.455 respectively). Sham treatment also did not have any significant changes in P2y1 or P2x3 
gene expression (F(2,11) = 0.238, p = 0.792, F(2,11) = 0.641, p = 0.545, respectively).  
There was no effect of injury condition on expression of P2y1 or P2x3 at 1 day post-SCI 
(F(1,7) = 1.018, p = 0.347; F(1,7) = 3.266, p = 0.114, respectively) or at 7 days post-SCI (F(1,9) 
= 0.036, p = 0.854; F(1,9) = 0.112, p = 0.746, respectively) (Figure 5). 
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Piezo-type mechanosensitive ion channel component 2.  We also assessed Piezo2 
(Figure 6). Severe injury condition, moderate injury condition, and sham treatment all had no 
significant changes in Piezo2 expression (F(2,10) = 1.662, p = 0.238; F(2,10) = 0.676, p = 0.530; 
F(2,11) = 2.084, p = 0.171, respectively). 
There was no effect of injury condition on expression of Piezo2 at either 1 day post-SCI 
(F(1,7) = 0.818, p = 0.396) or 7 days post-SCI (F(1,9) = 0.274, p = 0.614) (Figure 6). 
Calcitonin-related polypeptide alpha.  Lastly, we examined changes in Calca 
expression (Figure 6). Severe injury condition, moderate injury condition, and sham treatment all 
had no significant changes in Calc expression (F(2,10) = 1.784, p = 0.218; F(2,10) = 0.638, p = 
0.548; F(2,11) = 0.772, p = 0.485, respectively). 
There was no effect of injury condition on Calc expression at 1 day post-SCI (F(1,7) = 
2.040, p = 0.196), but there was a significant effect at 7 days post-SCI (F(1,9) = 6.832, p = 
0.028) (Figure 6). Calc expression was greater at the moderate injury condition (M = 4.95, SD 
= 4.31) compared to the severe injury condition (M = 0.40, SD = 0.18). 
Hematoxylin and Eosin Staining 
 When assessing for the presence of inflammation using hematoxylin and eosin stain on 
one naïve and one 1 day post-SCI colon tissue sections, we determined that there was no overt 
sign of inflammation due to no overt immune cell infiltration, no thickening of organ walls, and 
no loss of goblet cells (Wirtz et al., 2007) (Figure 7). The sections from each condition look 
nearly identical to each other, suggesting a lack of physical change in the colon at that early of a 
timepoint following SCI. The sample size is much smaller than it should be, but if it the trend 
holds true then this would suggest that any changes in target expression, especially in the 1 day 
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post-SCI condition, may be inflammation independent. More specifically, even though we are 
seeing differences in gene expression, it is not mimicked by morphological changes in the colon 
within the first 24 hours after injury. More subjects and more time-points needed to be assessed 
to make any solid conclusions. 
Discussion 
 We successfully analyzed a set of differentially expressed pain-related genes following 
SCI. The pattern of differentially expressed genes differed both as a result of injury condition 
and over time following SCI. In the severe injury condition, Gfrα2 increased in expression at 7 
days post-SCI compared to 1 day post-SCI while Trkc had sustained decreased expression 
following SCI. In the moderate injury and sham conditions, we detected decreases in both and 
Gfrα1 and Gfrα3, but decreased Asic2 expression only in the sham condition. Additionally, there 
were effects of specific injury condition on expression of several genes at 7 days post-SCI 
including Gfrα1, Gfrα3, Trkb, Asic1, and Calc with moderate injury condition demonstrating a 
pattern of higher expression compared to severe injury condition. These findings are important 
first steps in identifying potential injury- and time-sensitive therapeutic targets for better 
precision medicine in treating post-SCI visceral pain. 
We detected a significant increase in Gfrα2 expression at 7 days following SCI in the 
70kD, 10 second dwell time condition. Signaling between the GDNF family receptors and their 
respective ligands (GFRα1-GDNF, GFRα2-Neurturin, GFRα3-Artemin) are essential for 
neurodevelopment in the enteric, autonomic, and sensory systems (Baloh et al., 2000). Aside 
from their promotion of neural survival and proliferation, the GDNF family receptors have also 
emerged as important players in the realm of pain research. Previous findings indicate that these 
receptors are transcriptionally regulated by their respective ligand and, therefore, a feedback loop 
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exists that helps to ensure a change in the neurotrophic factor ligands corresponds to a change in 
neurotrophic response (Airaksinen & Saarma, 2002). Therefore, it is likely that in the context of 
the GDNF family receptors, their differences in transcription would be mimicked by differences 
in translation. In the context of other pain-associated pathologies, such as human pancreatic 
cancer, increased neural GFRα2 is associated with increased severity of pain in patients (Wang et 
al., 2014). Further, in models of inflammatory pain, GFRα2 knockout mice had a deficient 
inflammatory pain response, but normal responses to innocuous stimuli, suggesting an important 
role for GFRα2 in pathological pain responses (Lindfors et al., 2006). Based on these previous 
studies, we would predict that the increased Gfrα2 expression found in the colon could contribute 
to an increased visceral pain phenotype if translated into protein. This would mean that the colon 
would become more sensitive to the effects of neurotrophic factors, neurturin specifically.  
In the moderate injury condition (65kD, 1 second dwell time), there were significant 
decreases of both Gfrα1 and Gfrα3 early following injury with Gfrα1 maintaining low expression 
at the 7 day mark, but Gfrα3 recovering so that it was no longer significantly different from 
naïve. Similarly, sham animals also demonstrated decreased expression of both of these 
transcripts. Antisense oligodeoxynucleotides have been used against Gfrα1 mRNA causing an 
inhibition of induced muscle hyperalgesia (Alvarez et al., 2012). If this result was true for other 
pain models, it may suggest that decreased Gfrα1 may be analgesic in our SCI model. In a 
cutaneous inflammatory model, known to induce hyperalgesia, researchers reported increases in 
Gfrα3 mRNA, suggesting that Gfrα3 is likely important for the development of inflammation 
induced hyperalgesia (Malin et al., 2006). If more Gfrα3 is correlated to increased pain, then it’s 
possible that decreased Gfrα3 seen in our SCI model would be analgesic similar to Gfrα1. Next 
steps in following up on these findings would be to make sure the differences in mRNA 
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translated to differences in protein and to examine the amount of each ligand present in the colon 
following SCI to see if they match the expression of their respective receptors. Decreases in the 
receptors could mean decreased colon sensitivity to the influence of their neurotrophic factor 
ligands. Protein levels for the receptors and ligands could be assessed with Western blots or 
enzyme-linked immunosorbent assays (ELISAs) making sure to assess both injury conditions 
and the same time points used in the present study. 
 We were also able to detect a consistent decrease of Trkc expression following SCI in the 
70kD, 10 second dwell time condition. Signaling between the Trk family and their neurotrophic 
ligands (NGF-TrkA, BDNF-TrkB, NT-3-TrkC) is important for proper neural development and 
nociceptor function (Khan & Smith, 2015; Jankowski & Koerber, 2010; Shu et al., 1999). TrkC 
has specifically been shown to be expressed in both the enteric nervous system of the colon and 
sensory afferents (Lamballe et al., 1994; McMahon et al., 1994). Pain research involving TrkC 
and its ligand NT-3 have had conflicting results with some reporting anti-nociceptive effects in 
nerve injury and neuropathic pain models, but others showing pro-nociceptive effects in different 
conditions like colitis models (Jankowski & Koerber, 2010). In a model of skeletal pain, 
researchers demonstrated analgesic effects of a Trk inhibitor (Ghilardi et al., 2011). Although not 
TrkC specific, this finding could suggest that decreased Trkc in our SCI model would be anti-
nociceptive. Future experiments should examine protein levels of TrkC and its ligand NT-3 
following SCI at the same time points as this study using either Western blots or ELISAs.   
Multiple significant differences in gene expression were seen in sham animals including 
reductions of aforementioned Gfrα1 and Gfrα3, but also Asic2, known to be involved in 
detecting changes in pH, visceral mechanotransduction, and modulating pain responsiveness 
following inflammation (Lingueglia, 2007; Staniland & McMahon, 2012). How could a sham 
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surgery with no actual spinal cord damage cause any changes in pain-related genes in the colon? 
It is possible that the act of removing bone and bleeding in that area triggers a cascade of events 
in the spinal cord that could cause changes to the nearby dorsal root ganglia or central terminals 
of the sensory afferents. If there are changes to colon-specific DRG, which happen to be right 
below the surgery site, it’s possible that transcriptional effects in the cell body could also be seen 
down in the nerve terminals within the colon. Skeletal biology studies have demonstrated a 
release of pro-inflammatory mediators, such as prostaglandins, following bone fracture and 
pinning (Dekel et al., 1981). As mentioned earlier, pro-inflammatory mediators can increase 
sensitivity of sensory neurons (Woolf & Salter, 2000). If this is true, then even in a sham injury 
condition, the sensory afferents could experience changes in pain-related gene expression that 
corresponds to the gene differences we found in the present study. To further investigate this 
hypothesis, immunohistochemistry could be performed on sections of sham condition spinal 
cords and DRG to assess for the presence of pro-inflammatory mediators. Further, a different 
sham model without any bone removal could be used to determine if this would prevent the pain-
related gene expression changes we see in the current sham model. 
We found significant effects of injury condition on expression of Gfrα1, Gfrα3, Trkb, 
Asic1, and Calc  in the colon at the 7 day post-SCI time point. In all cases, expression was 
higher at the 65kD, 1 second dwell time injury than the 70kD, 10 second dwell time injury. If 
mimicked by more protein, there would be an increase sensitivity to neurotrophic factors, 
particularly GDNF, Artemin, and BDNF, as well as increased sensitivity to pH changes, peptides 
like CGRP, and visceral mechanotransduction compared to the higher injury (Khan & Smith, 
2015; Jankowski & Koerber, 2010; Shu et al., 1999; Han et al., 2015; Lingueglia, 2007). This 
finding could suggest that moderate injury conditions yield larger pain burdens, perhaps due to 
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more neural tracts left intact with lesser injuries. However, although we did see these differences 
in gene alterations, we cannot presently say that one injury is more severe than the other. Much 
of the current literature on SCI is performed in rats or primates, not mice. In order to say there 
was a difference in severity, a lesion reconstruction would have to be performed for both 
conditions and compared. 
While detecting gene expression changes in the colon following SCI is a good first step 
in identifying potential candidates for visceral pain involvement, there are several limitations to 
the present study. Firstly, the study is lacking any sort of assessment of a functional or behavioral 
outcome. We at least know that bowel function is maintained in SCI animals, however since 
we’re curious about a visceral pain phenotype, a good way to determine if it is present in our 
mouse SCI model would be to do colorectal distension (Christianson & Gebhart, 2007). This 
method measures the colon’s visceromotor response (VMR) via electromyograph (EMG) to 
specific pressures accomplished by inflation of a transanally inserted balloon. In models of other 
pathological abdominal pain phenotypes, animals typically demonstrate increased sensitivity to 
distension (Jones et al., 2007). Therefore, if SCI animals do have this phenotype, we would see 
increased VMR to distension pressures compared to naïve mice. We would at least test the two 
different injury levels and the time points used in this study, however it would be ideal to extend 
the time frame as far as 30 days or more as visceral pain can often develop at later times 
following injury (Finnerup & Baastrup, 2012). 
An additional limitation is that we only used female mice in the present study. This 
means that our results may not generalize to males with SCI. Although not SCI specific, there are 
some differences in pain processing between males and females which may mean there could be 
differences in expression of pain-related genes in peripheral tissues (Berkley, 1997). 
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It would also be important to determine the specific source of the differences in 
expression. There are many cell types present in the colon including autonomic nervous system 
terminals, sensory afferents terminals, the enteric nervous system, circulating immune cells, 
endocrine cells, as well as the cell types that help make up the colon including epithelial cells, 
connective tissue, and muscle (Canadian Cancer Society; Buffa et al., 1978; Janig & 
Koltzenburg, 1991; Murray et al., 2004; Furness, 2008; Turner, 2009). It is possible that several 
of these could be contributing to changes in gene transcripts. By using immunohistochemistry to 
stain sections of the colon for our candidate genes and different cell type markers, I would be 
able to locate the most likely cell type causing the results we see. In situ hybridization could also 
be a useful tool to determine the specific cell type contributing to expression differences. For 
these experiments, we would have to collect colon from shams and both injury levels at the same 
time points used in the present study, with naïve mice serving as a control. This would provide 
us with a visual representation of expression differences in cell types within the colon between 
injuries and in time. 
This study examined effects in the colon whole-tissue level, but not specifically how the 
colon sensory afferents may be changing due to SCI. There is a large possibility that the visceral 
pain phenotype seen in SCI patients is due to alterations in visceral afferent activity. Painful 
stimuli sensitive afferents, called nociceptors, transmit pain signals coming from the colon and 
other organs throughout the body (Basbaum et al., 2009). Nocicpetors are made up of two types 
of neurons: Aδ fibers which are myelinated and faster transmitting that are likely responsible for 
the initial sting of pain and C-fibers, which are small, unmyelinated, slow transmitting neurons 
responsible for poorly localized, later onset pain (Basbaum et al., 2009). C-fibers an also be 
divided into two subgroups, peptidergic and non-peptidergic, which are known to be mostly 
24 
 
polymodal (both heat and mechanically sensitive), but variation does exist (Basbaum et al., 
2009). Peptidergic fibers release peptides in response to stimulation (i.e. CGRP, Substance P) 
and are TrkA expressing (Basbaum et al., 2009). Non-peptidergic fibers do not express peptides 
and are both isolectin B4 (IB4) and c-Ret, a receptor responsive to GDNF family ligands, 
expressing (Basbaum et al., 2009). Using retrograde labeling, researchers have determined that 
the distribution of these subclasses in the colon specifically is approximately 80% peptidergic 
(CGRP expressing) and 20% non-peptidergic (IB4 expressing) (Robinson et al., 2004). By taking 
advantage of retrograde dyes injected into the colon, we could investigate what is happening 
strictly at the sensory afferent level through either immunohistochemistry or single-cell 
quantitative RT-PCR. To use single-cell quantitative RT-PCR, we would inject retrograde dye 
into the colon specific for the non-peptidergic (IB4) and peptidergic (WGA) populations, collect 
and dissociate the appropriate DRGs (T12/T13-L1, L5/6-S1), use fluorescent microscopy and a 
micromanipulator with electrodes to visualize and pick-up the backlabelled cells of different 
sizes, extract their RNA, and create a panel similar to the one in this study to see if any pain-
related transcripts are different following SCI. It would be important to begin with this 
exploratory method because the significantly different genes in the colon may not be the ones 
changing in the afferent cell body. This method would allow us to see what genes are 
differentially expressed on a nociceptor-type specific basis to see which type may be 
contributing more to the visceral pain phenotype following SCI. 
Once candidate genes are established, immunohistochemistry could be used to determine 
whether the differences in mRNA are mimicked by differences in protein. To do this, I could use 
the same retrograde dyes used in single-cell, collect, fix, and section the appropriate DRGs, and 
co-stain for the identified candidate genes. To go a step further, I could see if there were any 
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differences in candidate expression between the two sensory inputs for the colon, the splanchnic 
nerve and the pelvic nerve, as past studies have demonstrated that they differ in level of 
mechanical sensitivity, chemical sensitivity, and receptor expression (Brierley et al., 2004; 
Brierley et al., 2005). In vitro colon-nerve preps could also be used to assess any differences in 
physiological activity of these afferents that could contribute to post-SCI visceral pain (Shinoda 
et al., 2009). 
The present study is a first step in the process of identifying the source of the visceral 
pain following SCI. We demonstrated that a central injury like SCI can lead to peripheral effects 
in uninjured tissues. Even in assessing fifteen pain-related genes, we were able to detect time- 
and injury-dependent differences in expression. While there are many other targets to test and 
many next steps, the overarching goal is to one day create more specific and directed treatments 
for post-SCI pain in order to minimalize negative side effects from blanket-style drugs.  
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Gene Name Gene 
Symbol 
Forward and Reverse Primer 
Sequences (5’→3’) 
Product Size 
Acid sensing ion channel 1 Asic1 F: CAG-GCC-AGC-TCT-CCA-ATC-TC 
R: ACG-TAC-ACA-GGT-GAT-CTG-CC 
100 bp 
Acid sensing ion channel 2 Asic2 F: GCA-CCT-GTG-GAG-GAA-GTA-CG 
R: CCC-GCC-CCA-AAC-AAA-AAT-CAG 
111 bp 
Acid sensing ion channel 3 Asic3 F: GCA-ACA-CTC-TGC-TCC-AGG-AA 
R: CGA-GGT-AAC-AGG-TAC-GGT-GG 
135 bp 
Calcitonin-related polypeptide 
alpha 
Calc-α F: TGA-CAG-CAT-GGT-TCT-GGC-TT 
R: GTC-CCC-AGA-AGA-GCA-AGA-GG 
122 bp 
Glyceraldehyde 3-phosphate 
dehydrogenase 
Gapdh F: ATG-AAT-ACG-GCT-ACA-GCA-ACA-GG 
R: CTC-TTG-CTC-AGT-GTC-CTT-GCT-G 
105 bp 
GDNF family receptor alpha 
1 
Gfrα1 F: GAC-TCG-GAA-TCC-AGC-CTA-CG 
R: TCT-GCA-CTT-GTC-CTC-TCG-TG 
149 bp 
GDNF family receptor alpha 
2 
Gfrα2 F: CTT-GGG-GAG-AAG-GGC-TGT-TG 
R: AGG-AGA-AGA-GAG-AAG-GGG-CA 
102 bp 
GDNF family receptor alpha 
3 
Gfrα3 F: GCT-GGT-GTC-TTG-ACT-GCT-CT 
R: GAC-CCA-AGG-GAC-TAG-GGG-AA 
117 bp 
Purinergic receptor P2X 3 P2x3 F: GGT-GCC-TAA-GCC-TCT-TCT-GG 
R: AGG-GAT-GGC-GCT-GAG-TAA-AC 
163 bp 
Purinergic receptor P2Y 1 P2y1 F: GCC-AGG-ACA-CTA-ACC-CAT-CG 
R: AAC-TGA-AGG-CCC-ACA-AAC-CTC 
179 bp 
Piezo-type mechanosensitive 
ion channel component 2 
Piezo2 F: GAC-TGA-GGC-CAC-AGG-GCT 
R: GCA-AGG-AAA-ATG-TCA-CAC-ACT-G 
128 bp 
Tyrosine receptor kinase A Trka F: GAG-CCA-AGT-TTT-GGT-GCC-AG 
R: GAT-GCT-GGC-CAT-GAA-GCA-AG 
138 bp 
Tyrosine receptor kinase B Trkb F: AAG-ATG-TGT-CCC-TGG-GCT-TC 
R: AAG-TGA-GTC-ATG-AGC-TGC-C 
77 bp 
Tyrosine receptor kinase C Trkc F: CTG-CTC-CCC-ATG-GTT-GTA-GG 
R: GGG-AGG-CTG-GAA-ATG-AGG-TC 
149 bp 
Transient receptor potential 
ankyrin 1 
Trpa1 F: TGA-GCC-ACA-TGA-CAG-AAG-TCC 
R: CTA-AGC-AGC-AGC-AAC-AAC-TGG 
164 bp 
Transient receptor potential 
vanilloid 1 
Trpv1 F: GGC-GAG-ACT-GTC-AAC-AAG-ATT-GC 
R: TCA-TCC-ACC-CTG-AAG-CAC-CAC 
191 bp 
Table 1. Pain-related target genes, the forward and reverse primers used, and the PCR product size.  
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GDNF Family Receptors 
Figure 1. Changes in mRNA expression of the GDNF family receptors following SCI. a) For the severe injury condition (70kD, 10 second 
dwell time), we found a significant difference in expression between naïve, 1 day post-SCI, and 7 days post-SCI for Gfrα2 (F(2,10) = 5.502, p = 
0.024), but not Gfrα1 or Gfrα3 (F(2,10) = 3.661, p = 0.064; F(2,10) = 4.059, p = 0.051, respectively). Tukey’s HSD post-hoc analysis 
demonstrated elevated Gfrα2 expression at 7 days post-SCI compared to 1 day post-SCI (p = 0.020). b) Moderate injury condition (65kD, 1 
second dwell) had significant differences in expression of both Gfrα1 and Gfrα3 (F(2,10) = 6.460, p = 0.016; F(2,10) = 6.112, p = 0.018, 
respectively), but not Gfrα2 (F(2,10) = 2.050, p = 0.179). Tukey’s HSD post-hoc analysis determined that compared to naïve mice, both 1 day 
and 7 days post-SCI animals had decreases in Gfrα1 expression (p = 0.026; p = 0.019, respectively), but only 1 day post-SCI animals showed a 
decrease for Gfrα3 (p = 0.016). c) Sham surgery had significant changes in both Gfrα1 and Gfrα3 expression (F(2,11) = 11.431, p = 0.002; 
F(2,11) = 11.028, p = 0.002, respectively). Tukey’s HSD post-hoc showed that 1 day sham and 7 day sham animals both had decreases in Gfrα1 
expression (p = 0.003 for both) and Gfrα3 expression (p = 0.003; p = 0.005, respectively) compared to naïve. d) We found no significant 
differences in Gfrα1-3 expression at 1 day post-SCI between the two different injury conditions (F(1,7) = 0.659, p = 0.444; F(1,7) = 2.212, p = 
0.181; F(1,7) = 1.476, p = 0.264, respectively). e) There was a significant effect of injury condition on expression of both Gfrα1 and Gfrα3 
(F(1,9) = 5.546, p = 0.043; F(1,9) = 5.664, p = 0.041, respectively), but not Gfrα2 (F(1,9) = 2.015, p = 0.189). There was more Gfrα1 and Gfrα3 
expression in the moderate injury condition (M = 0.31, SD = 0.09; M = 0.49, SD = 0.31, respectively) than the severe injury condition (M = 0.18, 
SD = 0.09; M = 0.19, SD = 0.04). (* means p ≤ 0.05, ** means p ≤ 0.01, *** means p ≤ 0.001). 
a. b. c. 
d. e. 
* * 
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Tyrosine Kinase Receptors 
Figure 2. Changes in mRNA expression of the tyrosine kinase receptors following SCI. a) Severe injury condition had a significant 
alteration of Trkc expression (F(2,10) = 11.581, p = 0.002), but not of Trka or Trkb (F(2,10) = 0.915, p = 0.432; F(2,10) = 0.297, p = 0.749, 
respectively). Tukey’s HSD post-hoc analysis showed that, compared to naïve, 1 day post-SCI and 7 day post-SCI animals both had decreased 
expression of Trkc (p = 0.005; p = 0.003, respectively). b) Moderate injury condition did not demonstrate any significant changes in expression 
of Trka, Trkb, or Trkc (F(2,10) = 1.713, p = 0.229; F(2,10) = 3.870, p = 0.057; F(2,10) = 0.273, p = 0.767, respectively). c) Sham surgery did not 
demonstrate any significant changes in Trka, Trkb, or Trkc (F(2,11) = 0.453, p = 0.647; F(2,11) = 0.627, p = 0.552; F(2,11) = 2.623, p = 0.117, 
respectively). d) At day 1 post-SCI, there were no significant differences in expression of Trka-c (F(1,7) = 0.050, p = 0.830; F(1,7) = 3.260, p = 
0.114; F(1,7) = 1.868, p = 0.214, respectively). e) At 7 days post-SCI, there was no significant effect of injury level on Trka or Trkc expression 
(F(1,9) = 3.626, p = 0.089; F(1,9) = 3.825, p = 0.082, respectively), but there was on Trkb expression (F(1,9) = 6.395, p = 0.032). Trkb 
expression was higher in the moderate injury condition (M = 45.46, SD = 40.29) than the severe injury condition (M = 3.81, SD = 5.75). (* 
means p ≤ 0.05, ** means p ≤ 0.01, *** means p ≤ 0.001). 
a. b. c. 
d. e. 
* 
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Transient Receptor Potential Channels 
Figure 3. Changes in mRNA expression of the transient receptor potential channels following SCI. a) Severe injury condition demonstrated 
no significant changes in expression for either Trpv1 or Trpa1 (F(2,10) = 1.256, p = 0.326; F(2,10) = 0.562, p = 0.587, respectively). b) 
Moderate injury condition did not have any significant changes in Trpv1 or Trpa1 expression (F(2,10) = 1.633, p = 0.243; F(2,10) = 1.246, p = 
0.329, respectively). c) Sham treatment had no significant changes in expression of Trpv1 or Trpa1 either (F(2,11) = 0.255, p = 0.780; F(2,11) = 
2.761, p = 0.107, respectively). d) There was no effect of injury condition on expression of Trpv1 or Trpa1 at 1 day post-SCI (F(1,7) = 0.263, p = 
0.624; F(1,7) = 0.302, p = 0.600, respectively). e) There was no effect of injury condition on expression of Trpv1 or Trpa1 at 7 days post-SCI 
(F(1,9) = 3.255, p = 0.105; F(1,9) = 3.733, p = 0.085, respectively). 
a. b. c. 
d. e. 
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Acid Sensing Ion Channels 
Figure 4. Changes in mRNA expression of the acid sensing ion channels following SCI. a) There were no significant changes in expression 
of Asic1-3 in the severe injury condition (F(2,10) = 1.233, p = 0.332; F(2,10) = 0.716, p = 0.512; F(2,9) = 1.089, p = 0.377, respectively). b) 
Moderate injury condition did not have any significant changes in expression of Asic1-3 (F(2,10) = 3.140, p = 0.087; F(2,10) = 1.125, p = 0.363; 
F(2,9) = 1.152, p = 0.359, respectively). c) Sham surgery had no significant changes in expression of Asic1 and Asic3 (F(2,11) = 0.135, p = 
0.875; F(2,10) = 0.452, p = 0.649, respectively), however, Asic2 expression was significantly altered (F(2,11) = 12.241, p = 0.002). Tukey’s 
HSD post-hoc analysis determined that, compared to naïve, 1 day sham and 7 day sham both had decreased levels of Asic2 (p = 0.001; p = 0.016, 
respectively). d) There was no effect of injury condition on expression of Asic1-3 at 1 day post SCI (F(1,7) = 1.106, p = 0.328; F(1,7) = 0.790, p 
= 0.404; F(1,7) = 0.644, p = 0.449, respectively). e) Injury condition did significantly affect expression of Asic1 at 7 days post-SCI (F(1,9) = 
14.186, p = 0.004), but not Asic2 or Asic3 (F(1,9) = 0.743, p = 0.411; F(1,9) = 1.896, p = 0.202). Asic1 expression was greater at the moderate 
injury level (M = 2.47, SD = 1.16) than the severe injury level (M = 0.65, SD = 0.28). (* means p ≤ 0.05, ** means p ≤ 0.01, *** means p ≤ 
0.001). 
a. b. c. 
d. e. 
** 
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Purinergic Receptors 
Figure 5. Changes in mRNA expression of the purinergic receptors following SCI. a) Severe injury condition did not have any significant 
changes in P2y1 or P2x3 (F(2,10) = 0.880, p = 0.445; F(2,10) = 1.179, p = 0.347, respectively). b) Moderate injury conditionn did not display 
any significant changes in P2y1 or P2x3 expression (F(2,10) = 0.638, p = 0.548, F(2,10) = 0.854, p = 0.455, respectively). c) Sham surgery also 
did not have any significant changes in P2y1 or P2x3 gene expression (F(2,11) = 0.238, p = 0.792, F(2,11) = 0.641, p = 0.545, respectively). d) 
There was no effect of injury condition on expression of P2y1 or P2x3 at 1 day post-SCI (F(1,7) = 1.018, p = 0.347; F(1,7) = 3.266, p = 0.114, 
respectively). e) There was no effect of injury condition on expression of P2y1 or P2x3 at 7 days post-SCI (F(1,9) = 0.036, p = 0.854; F(1,9) = 
0.112, p = 0.746, respectively). 
a. b. c. 
d. e. 
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a. b. c. 
d. e. 
Piezo2 and Calc-α 
Figure 6. Changes in mRNA expression of Piezo2 and Calc-α following SCI. a) Severe injury condition had no significant changes in Piezo2 
or Calc-α expression (F(2,10) = 1.662, p = 0.238; F(2,10) = 1.784, p = 0.218). b) Moderate injury condition did not display any significant 
changes in Piezo2 or Calc-α expression (F(2,10) = 0.676, p = 0.530; F(2,10) = 0.638, p = 0.548, respectively). c) Sham surgery also did not have 
any significant changes in Piezo2 or Calc-α gene expression (F(2,11) = 2.084, p = 0.171; F(2,11) = 0.772, p = 0.485, respectively). d) There was 
no effect of injury condition on expression of Piezo2 at 1 day post-SCI (F(1,7) = 0.818, p = 0.396) or Calc-α (F(1,7) = 2.040, p = 0.196). e) 
There was no effect of injury condition on expression of Piezo2 at 7 days post-SCI (F(1,9) = 0.274, p = 0.614), but there was of Calc-α 
expression (F(1,9) = 6.832, p = 0.028) (Figure 6). Calc- expression was greater at the moderate injury condition (M = 4.95, SD = 4.31) 
compared to the severe injury condition (M = 0.40, SD = 0.18). (* means p ≤ 0.05, ** means p ≤ 0.01, *** means p ≤ 0.001). 
* 
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Naive 1 Day Post-SCI 
10X 
20X 
Figure 7. Lack of colon inflammation 1 day following SCI using hematoxylin and eosin stain. Cross sections of colon from naïve and 
greater injury severity 1 day post-SCI animals in order to assess for the presence of inflammation following SCI. There is no difference between 
the different conditions and, therefore, no inflammation early after SCI. 
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